Replies to post #449971 on Anavex Life Sciences Corp (AVXL)

[boi568]

I think we should distinguish between the status of the EXCELLENCE trial and the status of Anavex's Rett program. They seem to have been conflated.

EXCELLENCE did not meet its CGI-I endpoint, and had a nonfatal near miss on RSBQ. Unlike its 2b/3 AD trial, the company did not claim EXCELLENCE met its endpoints, except for safety. So that grades EXCELLENCE as a fail.

However, the RSBQ near miss was clearly affected by the placebo response, and the CGI-I may have failed based on a faulty trial design. Consequently, it can't be said that the Anavex Rett program has failed. Per the PR, which references the company's intent to explore Rett options with the FDA, this program is still alive.

[crescentmotor]

How about a little subtlety.

Not a bad idea. CPAs (like me) , and some other professions, are made up of folks that are anal attentive to details and that can lead to a desire to control an outcome/discussion. That can be a very rewarding trait in many professions. It also can be very annoying and overbearing to others and I understand that. I agree with your post 100%.